NASDAQ · XFOR
X4 Pharmaceuticals, Inc.
$3.36+$0.01 (+0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.43% below the high.
Loading market information…
NASDAQ · KYNB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Kyntra Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Kyntra Bio, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$3.55. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kyntra Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | $0.05-93.33% vs estimate | $2.70M+68.75% vs estimate |
|---|
| Q4 2024 | Mar 17, 2025 | -$4.50-125.0% vs estimate | $3.14M-87.41% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$4.25+44.5% vs estimate | $46.33M+32.98% vs estimate |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.36+$0.01 (+0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.43% below the high.
$29.08$0.00 (0.0%)
Mersana Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.31% below the high.
$2.62-$0.01 (-0.38%)
OnKure Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.3% below the high.
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
$7.29$0.00 (0.0%)
Kezar Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.44% below the high.
$7.77-$0.24 (-3.0%)
Xilio Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.26% below the high.
$1.53+$0.15 (+10.87%)
Actinium Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
$5.03-$0.14 (-2.71%)
Aligos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
